Maravai Lifesciences Holdings (MRVI) Income from Non-Controlling Interests (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly Income from Non-Controlling Interests of -$2.6 million in Q1 2026, up 90.33% quarter-over-quarter from -$27.3 million in Q4 2025, and up 88.46% on a YoY basis from -$1.4 million in Q1 2025.
Maravai Lifesciences Holdings (MRVI) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$2.6 million for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 88.46% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$79.7 million (up 37.26% YoY), while the FY2025 annual figure was -$100.0 million, up 12.88% from the prior year.
- Income from Non-Controlling Interests was -$2.6 million for Q1 2026 at Maravai Lifesciences Holdings, up from -$27.3 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $85.5 million in Q2 2022 to a low of -$75.4 million in Q3 2024.
- Historically, Income from Non-Controlling Interests has averaged $2.0 million across 5 years, with a median of -$8.6 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Income from Non-Controlling Interests tumbled 772.47% in 2024, then surged 88.46% in 2026.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $49.8 million in 2022, then sank by 108.08% to -$4.0 million in 2023, then plunged by 401.17% to -$20.2 million in 2024, then sank by 35.57% to -$27.3 million in 2025, then soared by 90.33% to -$2.6 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$2.6 million (Q1 2026), -$27.3 million (Q4 2025), and -$19.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 743.11 Mn | 734.71 Mn | 33.70 Mn | -2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.64 Mn |
| Dec 31, 2025 | -27.33 Mn |
| Sep 30, 2025 | -19.50 Mn |
| Jun 30, 2025 | -30.25 Mn |
| Mar 31, 2025 | -22.91 Mn |
| Dec 31, 2024 | -20.16 Mn |
| Sep 30, 2024 | -75.38 Mn |
| Jun 30, 2024 | -8.63 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Dec 31, 2023 | -4.02 Mn |
| Sep 30, 2023 | -8.64 Mn |
| Jun 30, 2023 | -5.40 Mn |
| Mar 31, 2023 | -1.28 Mn |
| Dec 31, 2022 | 49.80 Mn |
| Sep 30, 2022 | 55.18 Mn |
| Jun 30, 2022 | 85.48 Mn |
| Mar 31, 2022 | 80.00 Mn |
| Dec 31, 2021 | 71.28 Mn |
| Sep 30, 2021 | 78.22 Mn |
| Jun 30, 2021 | 85.35 Mn |